Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spriggs

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|March 25, 2011
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsGeorge R Simon, Robert L Ilaria, Mika A Sovak, et al.
ACS Chemical Biology|June 16, 2017
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer GrowthThapi Dharma Rao, Alberto Fernández-Tejada, Abram Axelrod, et al.
Investigational New Drugs|November 11, 2011
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphomaJason Konner, Rachel N Grisham, Jae Park, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2018
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian CancerKatherine LaVigne, David M Hyman, Qin C Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerPaul J Sabbatini, Govind Ragupathi, Chandra Hood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.
Journal of Ovarian Research|April 2, 2024
Sialyl-Tn serves as a potential therapeutic target for ovarian cancerLinah Al-Alem, Jillian M Prendergast, Justin Clark, et al.
British Journal of Cancer|May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trialsTomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2019
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stromaYanxia Zhao, Jinghong Cao, Alexander Melamed, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|March 25, 2011
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsGeorge R Simon, Robert L Ilaria, Mika A Sovak, et al.
ACS Chemical Biology|June 16, 2017
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer GrowthThapi Dharma Rao, Alberto Fernández-Tejada, Abram Axelrod, et al.
Investigational New Drugs|November 11, 2011
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphomaJason Konner, Rachel N Grisham, Jae Park, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2018
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian CancerKatherine LaVigne, David M Hyman, Qin C Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerPaul J Sabbatini, Govind Ragupathi, Chandra Hood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.
Journal of Ovarian Research|April 2, 2024
Sialyl-Tn serves as a potential therapeutic target for ovarian cancerLinah Al-Alem, Jillian M Prendergast, Justin Clark, et al.
British Journal of Cancer|May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trialsTomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2019
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stromaYanxia Zhao, Jinghong Cao, Alexander Melamed, et al.
Pageof 7